Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 17, 2019updated 23 Dec 2019 8:36am

hyperCORE International collaborates with VirTrial

Independent clinical research site network hyperCORE International has collaborated with VirTrial for a training programme.

Independent clinical research site network hyperCORE International has collaborated with VirTrial for a training programme.

The collaboration will make hyperCORE the first ‘Virtual Trial Capable’ site network in the world.

hyperCORE has more than 80 sites across five countries and two continents.

hyperCORE International and Benchmark Research CEO Mark Lacy said: “hyperCORE International is a proponent of meaningful change in how clinical trials are delivered to patients, ensuring that efficiencies are realised.

“The benefit of having the network trained and certified on virtual trials provides sponsors the option to conduct decentralised clinical trials within an experienced site network where they can maintain control over quality and standardisation across sites.”

The training programme contains four modules that need to be completed by clinical research professionals to demonstrate a level of competence in general telemedicine etiquette and guidelines.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Participants will then be issued with a Virtual Trial Capable certificate and badge, which is used by sponsors and CROs to identify those who are prepared to conduct hybrid decentralised clinical trials.

VirTrial Business Development vice-president Amanda Rangel said that the company is taking a grass-roots approach to decentralised clinical trials by aligning with sites and helping them prepare to transform from traditional trials to hybrid trials.

hyperCORE International COO Jeff Kingsley said: “Direct to patient clinical trials are a massive benefit to our industry and to the patients who give so much of themselves to help us learn and advance.

“Patients will have an easier time committing to the rigors of a clinical trial knowing that they can participate from the comfort of their own home or work.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy